Description
Anti-DEC-205 Antibody, Non-Fucosylated (BioBet-1197ZP) is a human monoclonal IgG antibody against DEC-205. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
APC-mediated Diseases
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced DEC-205 antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
LY75
Full Name
lymphocyte antigen 75
Alternative Names
LY75; lymphocyte antigen 75; CD205; LY-75; CLEC13B; DEC-205; GP200-MR6; C-type lectin domain family 13 member B
Gene ID
4065
Cellular Localization
Membrane
Involvement in Disease
Diseases associated with LY75 include Pneumonic Plague and Adenoiditis.
Related Pathways
Its related pathways are Dendritic Cells Developmental Lineage Pathway.
Function
As an endocytic receptor, the captured antigen is sent directly from the extracellular space to a dedicated antigen processing chamber (through similarity). Lead to a decrease in the proliferation of b lymphocytes.
Field of research
Controls and Markers antibody; Immune System antibody
Post-translational modifications
1.N-glycosylated 2.Modification sites at PhosphoSitePlus 3.Glycosylation at Asn135, Asn345, Asn377, Asn529, Asn843, Asn865, Asn934, Asn1076, Asn1103, Asn1225, Asn1320, Asn1392, Asn1593, Asn1626, and Asn1642
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG
Antibody Clone
3G9-2D2
Description
The monoclonal antibody which bind to human DEC-205 can be used in a variety of dendritic cell-targeted therapies, for example, to enhance antigen presentation and/or induce T cell responses, such as cytotoxic T cell (CTL) responses, against a variety of target cells or pathogens, or to treat antigen presenting cell (APC)-mediated diseases.
Antibody Indication
APC-mediated Diseases
